List of Excipients in Branded Drug PIVYA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alembic Pharmaceuticals Inc	PIVYA	pivmecillinam	62332-966	CELLULOSE, MICROCRYSTALLINE
Alembic Pharmaceuticals Inc	PIVYA	pivmecillinam	62332-966	HYDROXYPROPYL CELLULOSE
Alembic Pharmaceuticals Inc	PIVYA	pivmecillinam	62332-966	HYPROMELLOSE
Alembic Pharmaceuticals Inc	PIVYA	pivmecillinam	62332-966	MAGNESIUM STEARATE
Alembic Pharmaceuticals Inc	PIVYA	pivmecillinam	62332-966	PARAFFIN
UTILITY therapeutics Ltd	PIVYA	pivmecillinam	82546-200	CELLULOSE, MICROCRYSTALLINE

PIVYA Excipient Strategy and Commercial Opportunities for Pivmecillinam

Last updated: September 24, 2026

PIVYA is the U.S. brand for pivmecillinam, an oral beta-lactam antibiotic approved by the FDA in April 2024 for uncomplicated urinary tract infections in adult women caused by susceptible Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus.[1] Its commercial opportunity is tied to rising resistance among common uropathogens, limited oral treatment options, and the absence of a previously approved U.S. pivmecillinam product.

The excipient strategy is relatively conventional for an immediate-release film-coated tablet. The primary opportunities are not likely to come from novel excipients alone. They are more likely to involve tablet robustness, moisture control, taste and swallowability, dose flexibility, stability, supply-chain redundancy, and differentiated presentations for outpatient and public-health channels.

What is PIVYA and why does its formulation matter?

PIVYA contains pivmecillinam hydrochloride, a prodrug that is converted to mecillinam after oral administration. Mecillinam has selective activity against Gram-negative organisms, including many E. coli isolates associated with uncomplicated urinary tract infections.[1,2]

The FDA-approved product is an oral film-coated tablet. The labeled regimen is 185 mg orally three times daily for five days, with or without food.[1] This dosing schedule creates a formulation requirement that differs from once-daily chronic medicines:

• The tablet must tolerate repeated handling and daily dosing.
• Swallowability matters because patients take 15 tablets during a standard five-day course.
• Disintegration and dissolution must remain consistent across food conditions.
• The dosage form must support low manufacturing variability at commercial scale.
• Packaging must protect the product from moisture and physical damage during relatively high-frequency use.

For antibiotic products, excipient selection also affects manufacturing economics. A formulation that requires specialized granulation, unusually tight environmental controls, or imported excipient grades can weaken gross margins even when the active pharmaceutical ingredient is inexpensive.

What excipients are used in PIVYA tablets?

The FDA prescribing information identifies the following inactive ingredients for PIVYA tablets:

Formulation function	Excipient
Diluent and compression aid	Microcrystalline cellulose
Disintegrant	Croscarmellose sodium
Glidant	Colloidal silicon dioxide
Lubricant	Magnesium stearate
Film former	Hypromellose
Coating opacifier and pigment	Titanium dioxide
Coating anti-tacking agent	Talc
Colorant	Yellow ferric oxide

The tablet core uses a standard direct-compression or dry-processing excipient architecture. Microcrystalline cellulose supports compactibility, while croscarmellose sodium promotes tablet breakup after ingestion. Colloidal silicon dioxide can improve powder flow, and magnesium stearate reduces ejection friction during compression.[1]

The film coating supports identification, handling, and patient acceptability. Hypromellose is a widely used film-forming polymer. Titanium dioxide, talc, and yellow ferric oxide provide opacity, surface properties, and color.

These excipients are widely available through major pharmaceutical suppliers. That reduces the likelihood that the marketed product depends on a unique excipient technology. It also creates room for contract manufacturers and generic developers to pursue technically familiar alternatives, subject to bioequivalence and regulatory requirements.

How strong is the excipient and formulation protection for PIVYA?

The formulation protection of PIVYA should be analyzed separately from protection for pivmecillinam as an active moiety.

Pivmecillinam was developed outside the United States decades ago, and the underlying compound is not supported by a conventional new-compound patent term in the U.S. The commercial protection for PIVYA therefore depends on a combination of regulatory exclusivity, product-specific patents, manufacturing know-how, trademarks, supply arrangements, and market adoption.[1,3]

A conventional immediate-release tablet containing common excipients generally creates a narrower formulation barrier than:

• A controlled-release delivery system
• A long-acting injectable
• A combination product with a novel ratio
• A new crystalline form
• A proprietary amorphous dispersion
• A device-assisted delivery platform
• A formulation requiring a difficult or non-obvious manufacturing process

Common excipients do not by themselves establish strong freedom-to-operate protection. A competitor can often select alternative grades or substitute functionally equivalent excipients. The more defensible formulation claims, if available, would likely focus on a particular composition range, impurity profile, stability result, dissolution profile, manufacturing sequence, or tablet-coating process.

Which formulation attributes are commercially defensible?

The most valuable formulation attributes are likely to be:

1. Stability under ordinary pharmacy and patient storage conditions.
2. Rapid and reproducible dissolution.
3. Low tablet friability during distribution.
4. Reduced tablet size or improved swallowability.
5. Robustness against moisture-driven degradation.
6. Reliable performance across manufacturing sites.
7. Compatibility with high-volume, low-cost tableting equipment.

A reformulation that preserves the same active dose while reducing tablet size could have commercial value. The current three-times-daily regimen increases the practical importance of pill burden and patient adherence.

When does PIVYA lose exclusivity?

PIVYA received FDA approval on April 24, 2024, under NDA 216483.[1] The product was designated as a Qualified Infectious Disease Product, or QIDP, under the Generating Antibiotic Incentives Now framework. QIDP designation can provide a five-year extension to applicable regulatory exclusivity.[4]

Pivmecillinam was not previously marketed as an FDA-approved active ingredient in the United States. PIVYA therefore received new chemical entity exclusivity. The resulting statutory framework may provide a five-year NCE period plus a five-year QIDP extension, subject to the precise operation of the exclusivity provisions and any applicable regulatory limitations.[3,4]

Protection category	Key date or duration
FDA approval	April 24, 2024
Standard NCE exclusivity	Generally five years from approval
QIDP extension	Five additional years for qualifying exclusivity
Potential combined regulatory period	Approximately 10 years from approval
Expected regulatory exclusivity endpoint	Approximately April 2034, subject to FDA implementation

Regulatory exclusivity is not the same as patent protection. A competitor could potentially submit an abbreviated application after the relevant statutory restrictions expire, while patent disputes could affect the timing of approval or launch.

What is the Orange Book status of PIVYA?

PIVYA is approved under FDA NDA 216483 and is listed in FDA drug-label and product databases as a prescription oral tablet.[1,5]

Orange Book analysis should distinguish among:

• Patent listings for the reference product
• Regulatory exclusivity
• Paragraph IV certifications
• Label carve-outs for method-of-use claims
• Any pediatric exclusivity
• Any patent term extension

The principal commercial barrier currently visible from the regulatory record is PIVYA’s approval-based exclusivity and its QIDP status. Patent-listing conclusions should be based on the current Orange Book entry because listings can change through patent submissions, corrections, delistings, or FDA determinations.[5]

Are there Paragraph IV challenges to PIVYA?

A Paragraph IV challenge is a certification by an abbreviated new drug application applicant that a listed patent is invalid, unenforceable, or will not be infringed by the proposed product.[3]

PIVYA’s near-term Paragraph IV risk is constrained by the product’s 2024 launch and the time required for generic development, bioequivalence work, ANDA preparation, and FDA review. The risk profile can change if PIVYA-related patents are listed and generic applicants identify a commercially attractive market.

Potential generic challenge points include:

• Whether the proposed product matches the reference tablet’s inactive-ingredient profile.
• Whether dissolution performance is equivalent.
• Whether a listed formulation patent covers ordinary immediate-release tablets.
• Whether a method-of-use patent covers the full approved indication.
• Whether patent claims depend on a narrow excipient ratio or process step.
• Whether the ANDA applicant can use a label carve-out.

A generic manufacturer does not need to copy every excipient in the reference product. It generally needs to demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA pathway. That distinction limits the defensive value of a common-excipient formulation unless the formulation claims are narrow and technically specific.

What generic entry risks exist for PIVYA?

The main generic entry risks are regulatory, economic, and clinical rather than biologic.

Regulatory risk

Pivmecillinam is an older antibiotic with substantial non-U.S. clinical experience, but U.S. generic applicants would still need to satisfy FDA requirements for an ANDA or another applicable pathway. The reference product’s approval history may reduce some development uncertainty, but it does not eliminate formulation, analytical, or bioequivalence work.

Economic risk

Uncomplicated urinary tract infection is a high-volume indication. A generic entrant could compete on price if:

• The active ingredient is available from multiple qualified suppliers.
• Manufacturing uses standard tablet equipment.
• No difficult solid-state form is required.
• The generic can avoid costly clinical studies.
• Reimbursement supports substitution.

Clinical and market risk

PIVYA’s value proposition depends on use against resistant organisms and on physician familiarity with an antibiotic that has not historically been part of the U.S. outpatient formulary. Slow adoption would reduce the commercial incentive for early generic entry. Rapid formulary penetration would have the opposite effect.

What commercial opportunities exist for PIVYA excipients and formulations?

The largest opportunity is likely a platform strategy around differentiated oral antibiotic products rather than a single PIVYA copy.

Smaller tablet and adherence-oriented presentations

A smaller tablet or a high-load formulation could reduce the physical burden of three-times-daily dosing. Any such development would need to preserve dissolution, stability, and bioequivalence.

Moisture-protective packaging

Moisture-barrier blister packs, high-barrier bottles, and desiccant-based packaging may create practical value even without changing the tablet composition. Packaging can protect tablet integrity, reduce degradation risk, and support distribution through retail pharmacies and public-health stockpiles.

Pediatric or liquid dosage forms

PIVYA is approved for adult women. A pediatric suspension or dispersible dosage form could expand treatment access if supported by clinical and regulatory development. The excipient burden would increase because a liquid product requires control of taste, sedimentation, microbial growth, viscosity, and chemical stability.

Potential liquid formulation components could include:

• Suspending agents
• Buffering systems
• Sweeteners
• Flavoring agents
• Preservatives
• Wetting agents

Pediatric development would require careful control of excipient exposure, particularly for preservatives, sweeteners, and flavor systems.

Alternative manufacturing processes

Dry granulation, roller compaction, and direct compression could provide manufacturing flexibility. A process that produces consistent tablets with fewer unit operations may reduce cost and improve supply reliability. Process patents are most valuable when they solve a measurable problem such as poor flow, sticking, low tablet strength, or degradation during coating.

Regional licensing and supply agreements

Pivmecillinam has established use in parts of Europe and other markets. U.S. commercialization creates opportunities for:

• Regional distribution licensing
• Government and public-health procurement
• Hospital and integrated-delivery-network contracts
• Contract manufacturing
• Dual-source API arrangements
• Antibiotic stewardship partnerships

The commercial case depends on balancing volume with stewardship. Antibiotics can have high public-health value without generating the unit volume associated with chronic therapies. Contracting and reimbursement design are therefore central to launch economics.

How does PIVYA compare with competing oral UTI antibiotics?

Product or class	Main commercial strength	Main limitation relative to PIVYA
Nitrofurantoin	Established first-line use and low cost	Limited by renal function, tissue distribution, and susceptibility
Trimethoprim-sulfamethoxazole	Familiar oral therapy	Resistance and allergy concerns
Fosfomycin	Single-dose administration	Variable susceptibility and use restrictions
Fluoroquinolones	Broad activity and tissue penetration	Safety concerns and stewardship restrictions
Oral beta-lactams	Familiar prescribing category	Variable efficacy and resistance
PIVYA	New U.S. oral option with activity against common Gram-negative uropathogens	Three-times-daily dosing and limited U.S. commercial history

PIVYA is most commercially differentiated where resistance or contraindications reduce the utility of older first-line choices. Its strongest opportunity is not necessarily to replace every existing therapy. It is to occupy a reliable oral-treatment position for susceptible uncomplicated infections when standard options are unsuitable.

What is the revenue exposure and launch outlook for PIVYA?

PIVYA’s revenue potential depends on four variables:

1. The size of the uncomplicated UTI treatment market.
2. The proportion of patients with organisms susceptible to pivmecillinam.
3. Prescriber adoption and formulary access.
4. Net price after rebates, discounts, and government contracting.

The product has a long potential regulatory protection window through approximately 2034, but commercial performance will depend on antibiotic stewardship and payer behavior. The most important near-term commercial milestones are formulary placement, susceptibility testing adoption, guideline inclusion, distributor availability, and evidence of reduced reliance on broader-spectrum antibiotics.

Key Takeaways

• PIVYA is pivmecillinam, an FDA-approved oral treatment for uncomplicated urinary tract infections in adult women.
• Its tablet uses standard pharmaceutical excipients, including microcrystalline cellulose, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, hypromellose, talc, titanium dioxide, and yellow ferric oxide.
• The strongest formulation opportunities involve tablet size, stability, dissolution, packaging, and manufacturing efficiency.
• PIVYA received approval on April 24, 2024, and has QIDP status that may extend applicable regulatory exclusivity by five years.
• The potential combined NCE and QIDP regulatory period reaches approximately April 2034, subject to statutory implementation.
• PIVYA is a small-molecule antibiotic, so biosimilar competition is not applicable.
• Generic risk will depend on the Orange Book patent record, formulation claims, ANDA development economics, and market adoption.
• Pediatric, liquid, dispersible, packaging, and manufacturing-process opportunities could expand the product’s commercial platform.
• The core market opportunity is resistant or otherwise difficult-to-treat uncomplicated UTI, not unrestricted replacement of established first-line antibiotics.

FAQs About PIVYA Excipient and Commercial Strategy

Can PIVYA be reformulated as a once-daily product?

A once-daily product would require a new pharmacokinetic and clinical development program unless an approved dosage regimen supported the change. Conventional immediate-release excipient substitution would not by itself justify once-daily dosing.

Does PIVYA have biosimilar competition?

No. Pivmecillinam is a small-molecule drug. Future competitors would generally use the generic-drug pathway rather than the biosimilar pathway.

Could a generic manufacturer use different excipients from PIVYA?

Yes. An ANDA applicant generally does not need to duplicate every inactive ingredient, provided the proposed product satisfies applicable pharmaceutical-equivalence, bioequivalence, quality, and labeling requirements.

Is PIVYA suitable for a pediatric suspension?

The marketed product is approved for adult women. A pediatric liquid or dispersible formulation would require separate formulation, dosing, palatability, stability, safety, and regulatory development.

Which excipient presents the greatest commercial opportunity?

No single excipient is likely to create a major standalone opportunity. The strongest opportunity is an integrated formulation and packaging solution that improves moisture stability, tablet size, manufacturing yield, and patient adherence.

References

1. U.S. Food and Drug Administration. (2024). PIVYA (pivmecillinam hydrochloride) tablets, prescribing information.
2. Livermore, D. M., & Woodford, N. (2006). The beta-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends in Microbiology, 14(9), 413-420.
3. U.S. Food and Drug Administration. (2023). Orange Book: Approved drug products with therapeutic equivalence evaluations.
4. U.S. Food and Drug Administration. (2024). Qualified infectious disease product designation and exclusivity provisions.
5. U.S. Food and Drug Administration. (2024). Drugs@FDA: PIVYA, NDA 216483.